Arteris CFO Nicholas Hawkins sells $5,637 in stock

Published 07/03/2025, 23:12
Arteris CFO Nicholas Hawkins sells $5,637 in stock

Nicholas B. Hawkins (NASDAQ:HWKN), the Vice President and Chief Financial Officer of Arteris , Inc. (NASDAQ:AIP), a company maintaining strong gross profit margins of nearly 90% and a healthy balance sheet with more cash than debt, has sold a portion of his holdings in the company. According to InvestingPro analysis, the stock is currently trading above its Fair Value amid a challenging week that saw shares decline over 13%. According to a recent SEC filing, Hawkins sold 690 shares of common stock on March 6, 2025, at a price of $8.17 per share, totaling $5,637. This transaction was conducted under a 10b5-1 trading plan, which provides a pre-determined schedule for selling stocks, adopted by Hawkins on May 20, 2024. Following this sale, Hawkins holds 185,433 shares of Arteris stock directly. For comprehensive insider trading analysis and additional insights, including 7 more exclusive ProTips, check out the detailed research report available on InvestingPro.

In other recent news, Arteris, Inc. has been the focus of analysts following its recent product launches and market activities. Jefferies has adjusted its price target for Arteris to $11.00, up from $7.00, while maintaining a Hold rating. This adjustment reflects Arteris’ progress in the microcontroller unit market and the introduction of its FlexGen solution, which is expected to increase the average selling price per license by 30%. Northland analysts also raised their price target for Arteris, increasing it to $16.00 from $14.00, and maintained an Outperform rating. They highlighted that Arteris’ revenue met expectations, with bookings around $33.6 million for the quarter, and a book-to-bill ratio of 2.2:1. The FlexNoC 5 product accounted for a significant portion of the interconnect licenses, showing strong market traction. The launch of FlexGen, which 13 customers are currently evaluating, is seen as a driver for future revenue growth. Both firms noted the potential impact of FlexGen on Arteris’ financial performance, with Northland expressing confidence in the company’s market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.